- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/755 - Facteurs VIII
Détention brevets de la classe C07K 14/755
Brevets de cette classe: 844
Historique des publications depuis 10 ans
|
63
|
72
|
57
|
74
|
56
|
50
|
50
|
45
|
39
|
41
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Bioverativ Therapeutics Inc. | 214 |
89 |
| Takeda Pharmaceutical Company Limited | 2717 |
58 |
| Octapharma AG | 203 |
26 |
| Novo Nordisk A/S | 2287 |
21 |
| The Children's Hospital of Philadelphia | 810 |
18 |
| Baxalta Incorporated | 302 |
15 |
| CSL Behring GmbH | 346 |
15 |
| CSL Limited | 255 |
15 |
| St. Jude Children's Research Hospital | 241 |
15 |
| CSL Behring Lengnau AG | 126 |
15 |
| The Trustees of the University of Pennsylvania | 4384 |
14 |
| Bayer HealthCare LLC | 1328 |
13 |
| Baxalta GmbH | 104 |
13 |
| Emory University | 1660 |
13 |
| Baxter International Inc. | 2413 |
11 |
| Georgia Tech Research Corporation | 2828 |
11 |
| BioMarin Pharmaceutical Inc. | 381 |
11 |
| UCL Business Ltd | 632 |
11 |
| Baxter Healthcare S.A. | 1838 |
10 |
| Spark Therapeutics, Inc. | 171 |
9 |
| Autres propriétaires | 441 |